Yang Liu1, Xiang Hu, Hongguang Liu, Lihong Bu, Xiaowei Ma, Kai Cheng, Jinbo Li, Mei Tian, Hong Zhang, Zhen Cheng. 1. Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, Center of Excellence in Medical Molecular Imaging of Zhejiang State, Hangzhou, China; and.
Abstract
UNLABELLED: Radiolabeled bombesin (BBN) analogs that bind to the gastrin-releasing peptide receptor (GRPR) represent a topic of active investigation for the development of molecular probes for PET or SPECT of prostate cancer (PCa). RM1 and AMBA have been identified as the 2 most promising BBN peptides for GRPR-targeted cancer imaging and therapy. In this study, to develop a clinically translatable BBN-based PET probe, we synthesized and evaluated (18)F-AlF- (aluminum-fluoride) and (64)Cu-radiolabeled RM1 and AMBA analogs for their potential application in PET imaging of PCa. METHODS: 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-conjugated RM1 and AMBA were synthesized and tested for their GRPR-binding affinities. The NODAGA-RM1 and NODAGA-AMBA probes were further radiolabeled with (64)Cu or (18)F-AlF and then evaluated in a subcutaneous PCa xenograft model (PC3) by small-animal PET imaging and biodistribution studies. RESULTS: NODAGA-RM1 and NODAGA-AMBA can be successfully synthesized and radiolabeled with (64)Cu and (18)F-AlF. (64)Cu- and (18)F-AlF-labeled NODAGA-RM1 demonstrated excellent serum stability and tumor-imaging properties in the in vitro stability assays and in vivo imaging studies. (64)Cu-NODAGA-RM1 exhibited tumor uptake values of 3.3 ± 0.38, 3.0 ± 0.76, and 3.5 ± 1.0 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1.5, and 4 h after injection, respectively. (18)F-AlF-NODAGA-RM1 exhibited tumor uptake values of 4.6 ± 1.5, 4.0 ± 0.87, and 3.9 ± 0.48 %ID/g at 0.5, 1, and 2 h, respectively. CONCLUSION: The high-stability, efficient tumor uptake and optimal pharmacokinetic properties highlight (18)F-AlF-NODAGA-RM1 as a probe with great potential and clinical application for the PET imaging of prostate cancer.
UNLABELLED: Radiolabeled bombesin (BBN) analogs that bind to the gastrin-releasing peptide receptor (GRPR) represent a topic of active investigation for the development of molecular probes for PET or SPECT of prostate cancer (PCa). RM1 and AMBA have been identified as the 2 most promising BBN peptides for GRPR-targeted cancer imaging and therapy. In this study, to develop a clinically translatable BBN-based PET probe, we synthesized and evaluated (18)F-AlF- (aluminum-fluoride) and (64)Cu-radiolabeled RM1 and AMBA analogs for their potential application in PET imaging of PCa. METHODS:1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-conjugated RM1 and AMBA were synthesized and tested for their GRPR-binding affinities. The NODAGA-RM1 and NODAGA-AMBA probes were further radiolabeled with (64)Cu or (18)F-AlF and then evaluated in a subcutaneous PCa xenograft model (PC3) by small-animal PET imaging and biodistribution studies. RESULTS:NODAGA-RM1 and NODAGA-AMBA can be successfully synthesized and radiolabeled with (64)Cu and (18)F-AlF. (64)Cu- and (18)F-AlF-labeled NODAGA-RM1 demonstrated excellent serum stability and tumor-imaging properties in the in vitro stability assays and in vivo imaging studies. (64)Cu-NODAGA-RM1 exhibited tumor uptake values of 3.3 ± 0.38, 3.0 ± 0.76, and 3.5 ± 1.0 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1.5, and 4 h after injection, respectively. (18)F-AlF-NODAGA-RM1 exhibited tumor uptake values of 4.6 ± 1.5, 4.0 ± 0.87, and 3.9 ± 0.48 %ID/g at 0.5, 1, and 2 h, respectively. CONCLUSION: The high-stability, efficient tumor uptake and optimal pharmacokinetic properties highlight (18)F-AlF-NODAGA-RM1 as a probe with great potential and clinical application for the PET imaging of prostate cancer.
Entities:
Keywords:
18F-AlF; GRPR; PET; bombesin; prostate cancer
Authors: Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever Journal: Bioconjug Chem Date: 2008-09-23 Impact factor: 4.774
Authors: Lei Jiang; Richard H Kimura; Zheng Miao; Adam P Silverman; Gang Ren; Hongguang Liu; Peiyong Li; Sanjiv Sam Gambhir; Jennifer R Cochran; Zhen Cheng Journal: J Nucl Med Date: 2010-02 Impact factor: 10.057
Authors: William J McBride; Robert M Sharkey; Habibe Karacay; Christopher A D'Souza; Edmund A Rossi; Peter Laverman; Chien-Hsing Chang; Otto C Boerman; David M Goldenberg Journal: J Nucl Med Date: 2009-05-14 Impact factor: 10.057
Authors: Jered C Garrison; Tammy L Rold; Gary L Sieckman; Farah Naz; Samantha V Sublett; Said Daibes Figueroa; Wynn A Volkert; Timothy J Hoffman Journal: Bioconjug Chem Date: 2008-08-20 Impact factor: 4.774
Authors: Kinzya Grant; Maria L Lindenberg; Haytham Shebel; Yuxi Pang; Harsh K Agarwal; Marcelino Bernardo; Karen A Kurdziel; Baris Turkbey; Peter L Choyke Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-07 Impact factor: 9.236
Authors: Qian Wang; Kazuhiro Onuma; Changhao Liu; Heidi Wong; Michelle S Bloom; Eileen E Elliott; Richard Rl Cao; Nick Hu; Nithya Lingampalli; Orr Sharpe; Xiaoyan Zhao; Dong Hyun Sohn; Christin M Lepus; Jeremy Sokolove; Rong Mao; Cecilia T Cisar; Harini Raghu; Constance R Chu; Nicholas J Giori; Stephen B Willingham; Susan S Prohaska; Zhen Cheng; Irving L Weissman; William H Robinson Journal: JCI Insight Date: 2019-09-19
Authors: Francesco Blasi; Bruno L Oliveira; Tyson A Rietz; Nicholas J Rotile; Helen Day; Richard J Looby; Ilknur Ay; Peter Caravan Journal: J Nucl Med Date: 2014-05-01 Impact factor: 10.057
Authors: Haiming Ding; Shankaran Kothandaraman; Li Gong; Michelle M Williams; Wessel P Dirksen; Thomas J Rosol; Michael F Tweedle Journal: Prostate Date: 2016-03-04 Impact factor: 4.104
Authors: Benjamin B Kasten; Xiaowei Ma; Kai Cheng; Lihong Bu; Winston S Slocumb; Thomas R Hayes; Steven Trabue; Zhen Cheng; Paul D Benny Journal: Bioconjug Chem Date: 2015-12-30 Impact factor: 4.774